Know Labs, Inc. (KNWN)
- Business Wire
Know Labs, Inc. Announces Closing of $8.28 Million Public Offering of Common Stock
SEATTLE, September 20, 2022--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the closing of its underwritten public offering of 4,140,000 shares of its Common Stock at a public offering price of $2.00 per share, which includes the exercise by the underwriter of its over-allotment option to purchase up to 540,000 shares. The gross proceeds from this offering, before deducting underwriting discounts and commissions and othe
- Business Wire
Know Labs, Inc. Announces NYSE American Listing Approval
SEATTLE, September 13, 2022--Know Labs, Inc. (OTCQB: KNWN), an emerging leader of non-invasive medical diagnostic technology, today announced that, subject to official authorization and meeting all requirements (including the price requirement) at the time of listing, the Company has been approved to uplist to the NYSE American Exchange in conjunction with an underwritten public offering of the Company’s common stock. Upon the start of trading on the NYSE American, the ticker symbol for Know Lab
- Business Wire
Know Labs Provides Update on IRB-Approved Internal Trial of Non-Invasive Glucose Monitoring Technology
SEATTLE, September 02, 2022--Know Labs, Inc. (OTCQB: KNWN), an emerging developer of non-invasive medical diagnostic technology, today released a video update on the IRB-approved internal trial the Company has been conducting at its laboratory in Seattle. The video can be found here.
